EGFR and non-small cell lung carcinoma: Taken together, these results indicated that the acquired T790M mutation is a key factor associated with OS in advanced EGFR-mutated NSCLC patients receiving 1st-generation or 2nd-generation EGFR-TKIs as first-line therapies.